Form 4: GeneDx CFO Kevin Feeley Sells Shares Under 10b5-1 Trading Plan

GeneDx Holdings Corp. CFO Kevin Feeley sold a total of 1,430 shares of Class A Common Stock on January 2, 2025, under a pre-arranged 10b5-1 trading plan.

Summary

• Kevin Feeley, the Chief Financial Officer of GeneDx Holdings Corp., sold 1,430 shares of Class A Common Stock on January 2, 2025.
• The sales were executed under a Rule 10b5-1 trading plan adopted on August 21, 2024.
• The shares were sold in multiple transactions at weighted average prices of $75.0757, $76.0004, and $77.0427.
• The total number of shares owned by Mr. Feeley after the transactions is 26,770.

Sentiment

Score: 5

Explanation: The document reports a routine insider stock sale under a pre-arranged plan, which is neither particularly positive nor negative.

Risks

• Sales by company insiders, even under pre-arranged plans, can sometimes be perceived negatively by the market.

Industry Context

Insider trading activity is a common occurrence in publicly traded companies, and these transactions are closely monitored by regulators and investors. The use of 10b5-1 trading plans is a common way for insiders to sell shares while avoiding accusations of trading on non-public information.

Comparison to Industry Standards

• It is common for executives at publicly traded companies to use 10b5-1 trading plans to manage their personal finances and avoid accusations of insider trading.
• The volume of shares sold by Mr. Feeley is relatively small compared to the overall market capitalization of GeneDx Holdings Corp.
• Similar transactions are regularly reported by executives at comparable companies in the biotechnology and healthcare sectors.

Stakeholder Impact

• The stock sale may have a minor impact on shareholder sentiment, but it is unlikely to have a significant effect on the company's operations or financial performance.

Key Dates

Keywords

GeneDx, Kevin Feeley, insider trading, Form 4, 10b5-1, stock sale, CFO, WGS